Corporate Banner
Satellite Banner
Chromatography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Microsaic Systems Appoints Colin Jump as New CEO

Published: Tuesday, November 06, 2012
Last Updated: Tuesday, November 06, 2012
Bookmark and Share
Company to drive the commercialization of its revolutionary chip-based technology.

With over 30 years of experience working in the analytical instrumentation sector, Colin has a proven track record helping companies to achieve significant growth and will bring a vast amount of commercial and operational acumen to the role.

Prior to joining Microsaic, Colin was responsible for developing and growing Shimadzu UK Ltd, a global manufacturer of scientific research instruments.

As UK Managing Director of Shimadzu UK Ltd for the past 11 years, Colin led the company using his extensive business experience and industry knowledge to implement comprehensive growth and marketing communication strategies, both of which will be invaluable in the development and growth of Microsaic Systems going forward.

Before managing Shimadzu UK Ltd, Colin was European Commercial Director at SGE Europe Ltd, which followed seven years in senior management and marketing positions at Mallinckrodt Baker in the UK and the Netherlands.

In addition, his prior roles in sales and marketing positions at Bayer Diagnostics, Boehringer Mannheim UK and Wellcome Diagnostics will undoubtedly be beneficial to Mircosaic Systems as it looks to establish its innovative chip-based scientific instruments within the analytical instrumentation market.

“Microsaic Systems is the first and only company to have commercialized MS (mass spectrometry) technology on a chip,” said Colin Jump.

“This places the company in an optimal position to deliver this gold standard technique for chemical analysis to a much wider range of users and applications.”

He continues, “I am excited to be joining Microsaic Systems at this crucial stage as it accelerates the commercialization of its revolutionary chip-based technology. With the ability to address major opportunities across multiple market areas I see huge potential for the technology and for the Company in the years ahead.”

“Our breakthrough product, the 3500 MiD, represents a step change in the ease of use and footprint of mass spectrometry. The instrument is smaller, lighter, consumes less energy, is easier to maintain and cheaper to run than conventional MS systems,” comments Eric Yeatman, Acting CEO of Microsaic Systems.

Yeatman continued, “The Board is very pleased to welcome Colin Jump to the company as our new CEO and I have no doubt his commercial and operational experience in the analytical instrumentation sector will help drive the business forward towards the further realization of our corporate goals.”

The 3500 MiD is the culmination of over a decade of research, bringing together two high tech fields - chemical analysis and silicon micro-engineering - to make possible a transformative capability in detection.

Its low operating cost and small footprint make the 3500 MiD deployable in a wide range of applications where mass spectrometry has not been able to reach - until now.

Colin Jump will take up his role on 5th November 2012, at which point Eric Yeatman and Colin Nicholl will resume their former roles as Chairman and Deputy Chairman, respectively.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Grant to Fund Million Peaks Project
The European Research Council (ERC) has awarded a prestigious Advanced Grant to Prof. Peter Schoenmakers, Prof. Albert Polman and Prof. Huib Bakker, all three of whom work at the University of Amsterdam (UvA).
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Why Bearcats Smell Like Buttered Popcorn
Researchers pinpoint chemical compound that gives rare animal its popcorn-like scent.
Human Gut Microbiome Evolution
Westerners have a less-diverse gut microbiome compared to hunter-gatherers, but how and why these microbe collections diverged has largely remained a mystery.
Potential Diagnostic for Dengue Fever
Scientists from Colorado State University have explored the use of small molecules in patient serum for diagnosis of dengue fever and potentially predicting progression to the severe disease.
Non-Destructive Sensing of Fish Freshness
Is there any reliable way to know whether frozen fish is fresh or not?
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Portable Kit Can Recover Traces of Chemical Evidence
A chemist at the National Institute of Standards and Technology (NIST) has developed a portable version of his method for recovering trace chemicals such as environmental pollutants and forensic evidence including secret graves and arson fire debris.
Diagnosis of Two Rare Childhood Diseases Improved
For the first time, researchers have developed tests that could improve the diagnosis of two rare childhood diseases known as congenital disorders of glycosylation (CDGs) and metachromatic leukodystrophy, and that could even lead to new treatments for CDGs.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!